|
1
|
Randi G, Malvezzi M, Levi F, et al:
Epidemiology of biliary tract cancers: an update. Ann Oncol.
20:146–159. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Matsuda T and Marugame T: International
comparisons of cumulative risk of gallbladder cancer and other
biliary tract cancer, from Cancer Incidence in Five Continents Vol.
VIII. Jpn J Clin Oncol. 37:74–75. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leonard GD and O'Reilly EM: Biliary tract
cancers: Current concepts and controversies. Expert Opin
Pharmacother. 6:211–223. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Glimelius B, Hoffman K, Sjoden PO, et al:
Chemotherapy improves survival and quality of life in advanced
pancreatic and biliary cancer. Ann Oncol. 7:593–600. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eckel F and Schmid RM: Chemotherapy in
advanced biliary tract carcinoma: A pooled analysis of clinical
trials. Br J Cancer. 96:896–902. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al: ABC-02 Trial Investigators: Cisplatin plus gemcitabine
versus gemcitabine for biliary tract cancer. N Engl J Med.
362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kanai M, Hatano E, Kobayashi S, Fujiwara
Y, Sakai D, Kodama Y, Ajiki T, Nagano H and Ioka T: Phase I trial
of oral S-1 combined with gemcitabine and cisplatin for advanced
biliary tract cancer (KHBO1002). Cancer Chemother Pharmacol.
69:1181–1188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kanai M, Hatano E, Kobayashi S, Fujiwara
Y, Marubashi S, Miyamoto A, Shiomi H, Kubo S, Ikuta S, Yanagimoto
H, et al: A multi-institution phase II study of
gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for
patients with advanced biliary tract cancer (KHBO 1002). Cancer
Chemother Pharmacol. 75:293–300. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sia D, Tovar V, Moeini A and Llovet JM:
Intrahepatic cholangiocarcinoma: Pathogenesis and rationale for
molecular therapies. Oncogene. 32:4861–4870. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vauthey JN and Blumgart LH: Recent
advances in the management of cholangiocarcinomas. Semin Liver Dis.
14:109–114. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Okusaka T, Nakachi K, Fukutomi A, Mizuno
N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, et
al: Gemcitabine alone or in combination with cisplatin in patients
with biliary tract cancer: A comparative multicentre study in
Japan. Br J Cancer. 103:469–474. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ichinose Y, Yoshimori K, Sakai H, et al:
S-1 plus cisplatin combination chemotherapy in patients with
advanced non-small cell lung cancer: a multi-institutional phase II
trial. Clinical cancer research: an official journal of the
American Association for Cancer Research. 10:7860–7864. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Furuse J, Okusaka T, Boku N, Ohkawa S,
Sawaki A, Masumoto T and Funakoshi A: S-1 monotherapy as first-line
treatment in patients with advanced biliary tract cancer: A
multicenter phase II study. Cancer Chemother Pharmacol. 62:849–855.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sasaki T, Isayama H, Nakai Y, Ito Y,
Kogure H, Togawa O, Toda N, Yasuda I, Hasebe O, Maetani I, et al:
Multicenter, phase II study of gemcitabine and S-1 combination
chemotherapy in patients with advanced biliary tract cancer. Cancer
Chemother Pharmacol. 65:1101–1107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kanai M, Yoshimura K, Tsumura T, Asada M,
Suzuki C, Niimi M, Matsumoto S, Nishimura T, Nitta T, Yasuchika K,
et al: A multi-institution phase II study of gemcitabine/S-1
combination chemotherapy for patients with advanced biliary tract
cancer. Cancer Chemother Pharmacol. 67:1429–1434. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sasaki T, Isayama H, Nakai Y, Mizuno S,
Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O,
et al: Multicenter phase II study of S-1 monotherapy as second-line
chemotherapy for advanced biliary tract cancer refractory to
gemcitabine. Invest New Drugs. 30:708–713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim SW: The result of conversion surgery
in gastric cancer patients with peritoneal seeding. J Gastric
Cancer. 14:266–270. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Adam R, Wicherts DA, de Haas RJ, Ciacio O,
Lévi F, Paule B, Ducreux M, Azoulay D, Bismuth H and Castaing D:
Patients with initially unresectable colorectal liver metastases:
Is there a possibility of cure? J Clin Oncol. 27:1829–1835. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morganti AG, Massaccesi M, La Torre G,
Caravatta L, Piscopo A, Tambaro R, Sofo L, Sallustio G, Ingrosso M,
Macchia G, et al: A systematic review of resectability and survival
after concurrent chemoradiation in primarily unresectable
pancreatic cancer. Ann Surg Oncol. 17:194–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grendar J, Grendarova P, Sinha R and Dixon
E: Neoadjuvant therapy for downstaging of locally advanced hilar
cholangiocarcinoma: A systematic review. HPB Oxf. 16:297–303. 2014.
View Article : Google Scholar
|
|
21
|
Kato A, Shimizu H, Ohtsuka M, Yoshidome H,
Yoshitomi H, Furukawa K, Takeuchi D, Takayashiki T, Kimura F and
Miyazaki M: Surgical resection after downsizing chemotherapy for
initially unresectable locally advanced biliary tract cancer: A
retrospective single-center study. Ann Surg Oncol. 20:318–324.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Furukawa K, Uwagawa T, Sakamoto T, Shiba
H, Tsutsumi J and Yanaga K: Curative resection after gemcitabine,
cisplatin and S-1 chemotherapy for initially unresectable biliary
duct cancer: A case report. Anticancer Res. 35:4203–4206.
2015.PubMed/NCBI
|
